These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 8952151

  • 21. Serum transferrin receptor levels in beta-thalassemia trait.
    Demir A, Yarali N, Fisgin T, Duru F, Kara A.
    J Trop Pediatr; 2004 Dec; 50(6):369-71. PubMed ID: 15537726
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
    Italia KY, Jijina FJ, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.
    Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Soluble transferrin receptor following bone marrow transplantation from donors heterozygous for beta thalassemia.
    Centis F, Delfini C, Agostinelli F, Tonucci P, Gaziev J, Annibali M, Lucarelli G.
    Haematologica; 1994 Sep; 79(5):448-51. PubMed ID: 7843631
    [Abstract] [Full Text] [Related]

  • 26. Decreased expression of membrane alpha4beta1, alpha5beta1 integrins and transferrin receptor on erythroblasts in splenectomized patients with beta-thalassemia intermedia. Parallel assessment of serum soluble transferrin receptors levels.
    Kossiva L, Paterakis G, Tassiopoulos S, Papadhimitriou SI, Voukouti E, Gligori I, Rombos Y.
    Ann Hematol; 2003 Sep; 82(9):579-84. PubMed ID: 12904899
    [Abstract] [Full Text] [Related]

  • 27. Spectrum of beta thalassemia mutations and HbF levels in the heterozygous Moroccan population.
    Lemsaddek W, Picanço I, Seuanes F, Mahmal L, Benchekroun S, Khattab M, Nogueira P, Osório-Almeida L.
    Am J Hematol; 2003 Jul; 73(3):161-8. PubMed ID: 12827652
    [Abstract] [Full Text] [Related]

  • 28. Lipid profile in beta-thalassemia intermedia patients: correlation with erythroid bone marrow activity.
    Amendola G, Danise P, Todisco N, D'Urzo G, Di Palma A, Di Concilio R.
    Int J Lab Hematol; 2007 Jun; 29(3):172-6. PubMed ID: 17474893
    [Abstract] [Full Text] [Related]

  • 29. Molecular basis of thalassemia intermedia in Iran.
    Akbari MT, Izadi P, Izadyar M, Kyriacou K, Kleanthous M.
    Hemoglobin; 2008 Jun; 32(5):462-70. PubMed ID: 18932071
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
    Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P.
    Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
    [Abstract] [Full Text] [Related]

  • 32. A useful relationship between the presence of extramedullary erythropoeisis and the level of the soluble form of the transferrin receptor in a large cohort of adult patients with thalassemia intermedia: a prospective study.
    Ricchi P, Ammirabile M, Costantini S, Di Matola T, Verna R, Diano A, Foglia MC, Spasiano A, Cinque P, Prossomariti L.
    Ann Hematol; 2012 Jun; 91(6):905-9. PubMed ID: 22167341
    [Abstract] [Full Text] [Related]

  • 33. Serum soluble transferrin receptor in hypochromic microcytic anaemia.
    Jayaranee S, Sthaneshwar P.
    Singapore Med J; 2006 Feb; 47(2):138-42. PubMed ID: 16435056
    [Abstract] [Full Text] [Related]

  • 34. Increased CD177 (PRV1) expression in thalassaemia and the underlying erythropoietic activity.
    Zoi K, Terpos E, Zoi C, Loukopoulos D.
    Br J Haematol; 2008 Apr; 141(1):100-4. PubMed ID: 18324972
    [Abstract] [Full Text] [Related]

  • 35. Expression of human telomerase reverse transcriptase in bone marrow CD34+ cells from patients with beta-thalassemia major.
    Li X, Qu Y, Mao M, Yu F, Li Q, Hua Y, Mu D.
    Transfusion; 2008 Aug; 48(8):1627-33. PubMed ID: 18466174
    [Abstract] [Full Text] [Related]

  • 36. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators.
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [Abstract] [Full Text] [Related]

  • 37. Endogenous erythropoietin levels and anemia in long-term renal transplant recipients.
    Zadrazil J, Horák P, Horcicka V, Zahálková J, Strébl P, Hrubý M.
    Kidney Blood Press Res; 2007 May; 30(2):108-16. PubMed ID: 17374961
    [Abstract] [Full Text] [Related]

  • 38. Erythroid marrow activity and hemoglobin H levels in hemoglobin H disease.
    Papassotiriou I, Traeger-Synodinos J, Kanavakis E, Karagiorga M, Stamoulakatou A, Kattamis C.
    J Pediatr Hematol Oncol; 1998 May; 20(6):539-44. PubMed ID: 9856674
    [Abstract] [Full Text] [Related]

  • 39. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia.
    Gasche C, Waldhoer T, Feichtenschlager T, Male C, Mayer A, Mittermaier C, Petritsch W, Austrian Inflammatory Bowel Diseases Study Group.
    Am J Gastroenterol; 2001 Aug; 96(8):2382-7. PubMed ID: 11513178
    [Abstract] [Full Text] [Related]

  • 40. Serum transferrin receptor levels are increased in asymptomatic and mild Plasmodium falciparum-infection.
    Mockenhaupt FP, May J, Stark K, Falusi AG, Meyer CG, Bienzle U.
    Haematologica; 1999 Oct; 84(10):869-73. PubMed ID: 10509032
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.